Page 57 - 台灣肝癌醫學冬季會手冊-1222-V3_Neat

Subsequent locoregional therapy prolongs survival in progressive

hepatocellular carcinoma patients under lenvatinib treatment- the

real world experience

1,2
Po-Ting Lin , Shi-Ming Lin
1,2

1. Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital,

Linkou branch, Taiwan

2. College of Medicine, Chang Gung University, Taiwan

Abstract:

Background:

Locoregional therapy and multi-kinase inhibitor agent have been the backbone of

treatment for hepatocellular carcinoma (HCC) patients. However, the optimal

concurrent or subsequent regimen remain uncertain. Therefore, we aim to explore

whether the subsequent locoregional therapy provides better survival in HCC patients

under lenvatinib treatment.

Methods:

From March 2018 to April 2020, a total of 78 unresectable HCC patients receiving

lenvatinib were recruited. Tumor progression was evaluated by dynamic image using

the modified RECIST criteria. Locoregional therapy including radiofrequency

ablation (RFA) and transarterial chemoembolization (TACE) after lenvatinib

treatment were documented. Overall survival and the predictors for tumor progression

were analyzed.

Results:

Among the 78 patients receiving lenvatinib, the median age was 67.8 years old, and